Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.

NCT04768699 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A With Inhibitor
Hemophilia B With Inhibitor

Interventions

DRUG: TQG203
DRUG: TQG203/NovoSeven®
DRUG: TQG203

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.